|
Chronic liver disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Diagnostic value of serum cytokeratin-18 in children with chronic liver disease.
|
31054236 |
2020 |
|
Chronic lung disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Serum concentrations of CK-18 were significantly elevated in CLD patients with mean ± standard deviation (1070.63 ± 699.2 ng/mL) compared to healthy controls mean ± standard deviation (203.95 ± 83.57 ng/mL).
|
31054236 |
2020 |
|
Lymphoproliferative Disorder of the Skin
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Serum concentrations of CK-18 were significantly elevated in CLD patients with mean ± standard deviation (1070.63 ± 699.2 ng/mL) compared to healthy controls mean ± standard deviation (203.95 ± 83.57 ng/mL).
|
31054236 |
2020 |
|
Acute alcoholic liver disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Keratin 18 is a Diagnostic and Prognostic Factor for Acute Alcoholic Hepatitis.
|
31811953 |
2019 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, KRT18 serves as an oncogenic role in CRC progression and may be a therapeutic target for promoting CRC patients' prognosis.
|
31345960 |
2019 |
|
Disorders of Porphyrin Metabolism
|
0.010 |
Biomarker
|
group |
BEFREE |
Despite metabolic similarities most models (except those with chemically or genetically induced porphyria or keratin 18-deficiency) fail to develop the morphologic key features of NASH, namely hepatocyte ballooning and formation of histologically and immunohistochemically well-defined Mallory-Denk-Bodies (MDBs).
|
29746920 |
2019 |
|
Carcinoma breast stage IV
|
0.010 |
Biomarker
|
disease |
BEFREE |
Reduced cytokeratin 18 (CK18) expression is thought to be one of the hallmarks of EMT, and the role of CK18 in MDR of metastatic breast cancer remains unknown.
|
30896886 |
2019 |
|
Malignant neoplasm of gastrointestinal tract
|
0.010 |
Biomarker
|
disease |
BEFREE |
Prognostic value of non-invasive serum Cytokeratin 18 detection in gastrointestinal cancer: a meta-analysis.
|
31598152 |
2019 |
|
End Stage Liver Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Prediction of prognosis among DILI patients using the Model for End-Stage Liver Disease was improved by incorporation of K18 and MCSFR levels.
|
29357190 |
2019 |
|
Ischemic stroke
|
0.010 |
Biomarker
|
disease |
BEFREE |
Subacute Elevation of Plasma Level of Caspase-Cleaved Cytokeratin-18 is Associated with Hemorrhagic Transformation and Functional Outcome in Ischemic Stroke.
|
30528602 |
2019 |
|
Decompensated cirrhosis of liver
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, measurements of serum K18 or cK18 in HBV decompensated cirrhosis are a promising tool for predicting ACLF and risk stratification of short-term outcome.
|
30974482 |
2019 |
|
Acute-On-Chronic Liver Failure
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
HBV-AD patients without ACLF who admitted with upper tertile of K18 or cK18 were at higher risk of developing ACLF during follow-up.
|
30974482 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
KRT18 is correlated with the malignant status and acts as an oncogene in colorectal cancer.
|
31345960 |
2019 |
|
Adenocarcinoma of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Quantification of the heterogeneity of cytokeratin 18 immunoexpression in prostate adenocarcinoma and normal prostate: Global and local features.
|
29863745 |
2018 |
|
Primary biliary cirrhosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We investigated the association between cytokeratin-18 fragments (M30 and M65) and liver histology, treatment response and the development of cirrhosis-related conditions in patients with PBC.
|
29380060 |
2018 |
|
Cholelithiasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
miR-122 and keratin-18 plasma concentrations are elevated in patients with gallstones.
|
29703854 |
2018 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
Data on cytokeratin-18 (K-18) and enhanced liver fibrosis (ELF) score in insulin-treated diabetes patients with non-alcoholic fatty liver disease (NAFLD) are limited.
|
29167192 |
2018 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
Data on cytokeratin-18 (K-18) and enhanced liver fibrosis (ELF) score in insulin-treated diabetes patients with non-alcoholic fatty liver disease (NAFLD) are limited.
|
29167192 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
At onset, omentin-1 and CK-18 levels were higher than in any group of longstanding type 1 diabetes (p<0.025).
|
30179852 |
2018 |
|
Metabolic Syndrome X
|
0.010 |
Biomarker
|
disease |
BEFREE |
The elevated CK-18 serum levels in the HFD group and their association with the histological changes in the liver and biochemical indicators demonstrate the key role of apoptosis in the pathogenesis of HFD-induced liver damage and the reliability of CK-18 as a biomarker for noninvasive assessment of liver damages in MetS.
|
29989845 |
2018 |
|
Biliary Tract Cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we determined the efficacy of the cell death biomarker cytokeratin 18 for diagnosing biliary tract cancer (BTC).
|
30451962 |
2018 |
|
Cholecystolithiasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
miR-122 and keratin-18 plasma concentrations are elevated in patients with gallstones.
|
29703854 |
2018 |
|
Intestinal Graft Versus Host Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Serum levels of the apoptotic degradation product cytokeratin-18 fragments (CK18F) were associated with acute hepato-intestinal GVHD.
|
29950693 |
2018 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
We investigate the mechanism and advantages of the lifetime sensor in studies of the K18 protein fragment of the Alzheimer's disease related protein tau and its amyloid aggregates formed in vitro.
|
28073262 |
2017 |
|
Noninfiltrating Intraductal Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Most of these genes were highly expressed in DCIS samples with IBC, including PLAU (P = 0.002), COL1A1 (P = 0.006), KRT81 (P = 0.009), S100A7 (P = 0.015), SCGB1D2 (P = 0.023), KRT18 (P = 0.029), and NOTCH3 (P = 0.044), whereas EGFR and CXCL14 showed a higher expression in cases with pure DCIS (P = 0.015 and P = 0.028, respectively).
|
28634007 |
2017 |